Cargando…
P1295: ADVANTAGE OF FIRST-LINE TDM-DRIVEN USE OF INFLIXIMAB FOR TREATING ACUTE INTESTINAL AND LIVER GVHD IN CHILDREN: A PROSPECTIVE, SINGLE-CENTER STUDY.
Autores principales: | Maximova, Natalia, Nistico’, Daniela, Marcuzzi, Annalisa, Rimondi, Erika, Tessitore, Antimo, Riccio, Guglielmo, Barbi, Egidio, Paolo, Antonello DI |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430541/ http://dx.doi.org/10.1097/01.HS9.0000972068.73278.65 |
Ejemplares similares
-
Advantage of First-Line Therapeutic Drug Monitoring-Driven Use of Infliximab for Treating Acute Intestinal and Liver GVHD in Children: A Prospective, Single-Center Study
por: Maximova, Natalia, et al.
Publicado: (2023) -
Defibrotide impact on the acute GVHD disease incidence in pediatric hematopoietic stem cell transplant recipients
por: Squillaci, Domenica, et al.
Publicado: (2023) -
P1272: DEFIBROTIDE IMPACT ON THE ACUTE GRAFT-VERSUS-HOST DISEASE INCIDENCE IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS.
por: Squillaci, Domenica, et al.
Publicado: (2023) -
New Applications of JAK/STAT Inhibitors in Pediatrics: Current Use of Ruxolitinib
por: Marcuzzi, Annalisa, et al.
Publicado: (2022) -
Rapid recovery of postnivolumab vemurafenib-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome after tocilizumab and infliximab administration
por: Maximova, Natalia, et al.
Publicado: (2020)